Dov Pekelman replaces Hasmukh Shah on Taro's board
This article was originally published in Scrip
Executive Summary
Taro Pharmaceutical Industries, an Israel-based multinational pharmaceutical company developing a range of generic and branded drugs, has appointed Professor Dov Pekelman to its board until the next AGM of shareholders, to fill the vacancy left by Hasmukh Shah who has resigned from the board after one year's service for personal reasons. Professor Pekelman is currently chairman of Atera Networks and Gilon Investmments.